最新消息
News
HanchorBio Reports Preliminary First-Line HER2+ Gastric Cancer Data for HCB101, Demonstrating 83.3% ORR漢康生技公布HCB101 HER2陽性胃癌一線治療初步數據 ORR達 83.3%
Hanchorbio's preliminary clinical observations from its ongoing Phase 1b/2a study evaluating HCB101-based combination therapy in first-line HER2-positive gastric cancer.
4 月 01, 2026
Read more
HanchorBio Presents First Dedicated HCB101 Head and Neck Cancer Data in Oral Presentation at ICHNO 2026漢康生技於2026 ESMO頭頸癌年會首次以口頭發表 HCB101 頭頸癌臨床數據
HanchorBio announced the first dedicated presentation of HCB101 clinical data in head and neck squamous cell carcinoma (HNSCC) in an oral presentation at ICHNO 2026 (the 10th International Congress on Innovative Approaches in Head and Neck Oncology), a joint ESTRO, EHNS, and ESMO congress, in Seville, Spain.
3 月 20, 2026
Read more
HanchorBio Expands Global Patent Protection for HCB101 with Taiwan Grant漢康生技融合蛋白創新藥HCB101獲台灣專利核准
Taiwan grant adds to issued patents in the United States and Japan, further strengthening HCB101’s cross-border IP estate and supporting long-term development and partnering strategy.
3 月 17, 2026
Read more
HanchorBio Presents First Public Clinical Data for HCB301, a Tri-Specific Innate Checkpoint Molecule, at ESMO-TAT 2026漢康生技於 ESMO標靶抗癌治療大會首次公開 HCB301 人體臨床數據，展現三功能先天免疫檢查點分子的臨床開發潛力
HanchorBio, Inc. announced the presentation of first-in-human clinical data for HCB301 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
3 月 16, 2026
Read more
HanchorBio Highlights Advancing HCB101 Clinical Program Across Monotherapy and Combination Settings at ESMO-TAT 2026漢康生技於 ESMO標靶抗癌治療大會公布 HCB101 單藥與聯合治療臨床進展，展現作為先天免疫檢查點治療骨幹的潛力
HanchorBio announced the presentation of updated clinical data for HCB101 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
3 月 16, 2026
Read more
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress漢康生技於第11屆亞太胃食管癌大會發表 HCB101 三藥聯合療法於二線胃癌之具劑量依賴性的腫瘤反應與持續腫瘤縮小數據
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical data from its ongoing HCB101-201 Phase 1b/2a study at the 11th Asia-Pacific Gastroesophageal Cancer Congress (APGCC). The poster highlights early findings supporting dose-dependent antitumor activity of HCB101 in combination with ramucirumab and paclitaxel among patients with advanced gastric adenocarcinoma who progressed after first-line therapy.
3 月 05, 2026
Read more
HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026漢康生技於美國癌症研究協會 (AACR) 腫瘤免疫學年會發表 HCB101 單藥與聯合治療的臨床數據
HanchorBio Presents Monotherapy and Combination Clinica […]
2 月 19, 2026
Read more
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer漢康廣譜抗癌新藥HCB101獲孤兒藥認定 推進晚期胃癌新療法
HanchorBio Receives FDA Orphan Drug Designation for HCB […]
2 月 13, 2026
Read more
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
1 月 26, 2026
Read more
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101漢康生技創新 SIRPα/CD47 融合蛋白生物藥 HCB101 獲日本專利核准
HanchorBio Secures Japanese Patent for Engineered SIRPα […]
1 月 23, 2026
Read more